Self Study 2024 Release I: Ocular Toxicities with Antineoplastics
Ocular toxicities with cytotoxic chemotherapy have been well reported with most being low severity conjunctivitis, keratitis, optic neuritis or blurred vision. With the development of newer antineoplastics such as targeted therapy and immunotherapy, ocular toxicities have been increasingly described. These cancer therapies display distinct ocular toxicities with a class effect such as retinal vein occlusions with MEK inhibitors or uveitis with immune checkpoint inhibitors. Furthermore, within the past few years, multiple new antibody-drug conjugates have received regulatory approval but also display significant and possibly severe ocular toxicities with recommended ophthalmic monitoring. In this module, participants will explore various ocular adverse events associated with different classes of antineoplastics.
Ocular Toxicities with Antineoplastics
UAN# 0465-0000-24-076-H01-P
Author: Brandon Chang, PharmD, APh, BCPS, BCOP
Learning Objectives
- Recognize common and serious ocular adverse events associated with antineoplastics
- Describe the incidence of ocular toxicities for patients treated with targeted therapies and immune checkpoint inhibitors
- Compare the various strategies to prevent and manage ocular toxicities from antibody-drug conjugates
- Analyze efficacy and toxicity of the novel folate receptor alpha directed antibody-drug conjugate, mirvetuximab soravtansine
Get it
Knowledge Course for Pharmacists
Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy. In order to claim BCOP credit, you must pass the BCOP Post- Testwith a 75% or higher.
All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.